Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Mammotome

This article was originally published in The Gray Sheet

Executive Summary

Hand-held version of the minimally invasive breast biopsy device will be launched by Johnson & Johnson's Ethicon Endo-Surgery business this fall, following 510(k) clearance Sept. 1. The system will be priced comparably to the original Mammotome, which is mounted to an imaging table and has been available in the U.S. since 1995. The new version can perform biopsies more easily on a wider range of breast abnormalities, and allows for greater patient comfort, J&J claims
Advertisement

Related Content

Image-Guided Breast Biopsy Coverage Raises Palpable Fears For Surgeons
Image-Guided Breast Biopsy Coverage Raises Palpable Fears For Surgeons
Advertisement
UsernamePublicRestriction

Register

MT012266

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel